List of Remodulin drug patents

Remodulin is owned by United Therap.

Remodulin contains Treprostinil.

Remodulin has a total of 9 drug patents out of which 0 drug patents have expired.

Remodulin was authorised for market use on 21 May, 2002.

Remodulin is available in injectable;iv (infusion), subcutaneous dosage forms.

Remodulin can be used as administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration, a method of treating a human patient suffering from pulmonary hypertension, a method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer, administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration.

The generics of Remodulin are possible to be released after 29 March, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199908 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US9713599 UNITED THERAP Parenteral formulations of treprostinil
Dec, 2024

(1 year, 10 months from now)

US10076505 UNITED THERAP Inhalation formulations of Treprostinil
Dec, 2024

(1 year, 10 months from now)

US10695308 UNITED THERAP Inhalation formulations of treprostinil
Dec, 2024

(1 year, 10 months from now)

US8653137 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Sep, 2028

(5 years from now)

US8658694 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Sep, 2028

(5 years from now)

US7999007 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Mar, 2029

(6 years from now)

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 21 May, 2002

Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer; A method of treating a human patient suffering from pulmonary hypertension; Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration

Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS

How can I launch a generic of REMODULIN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in